Saoussen Zrour1, Amani Dridi1, Rim Grassa1
1Rheumatology Department, CHU Fattouma Bourguiba, Faculty of Medicine of Monastir, University of Monastir, Tunisia.
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Biologic disease-modifying antirheumatic drugs (bDMARDs) are primarily prescribed for axial spondylarthritis and rheumatoid arthritis in Tunisia. High costs associated with these advanced therapies present a considerable economic burden.
Area of Science:
Context:
Purpose:
Summary:
Impact: